背景：随着肿瘤干细胞研究的深入，肺癌干细胞成为目前研究的热点之一。目的：评价肿瘤干细胞标记物CD133在肺癌组织中的表达，以及与肺癌临床病理特征的关系。方法：应用免疫组化染色检测 CD133在不同类型、不同分化程度肺癌组织中的阳性表达率，并分析CD133阳性表达与肺癌患者年龄、性别、肿瘤大小、组织学类型、分期及分级、分化程度、淋巴转移和预后等临床病理特征的相关性。结果与结论：CD133在各种类型肺癌组织中均有较高的表达率，但是其阳性表达与肺癌患者的年龄、性别等患者临床特征无相关性，与肺癌的组织学分型、分期及分级、分化程度也无相关性，而与肺癌组织的淋巴转移及预后密切相关，伴有淋巴转移的肺癌组织中CD133的阳性表达率更高，且5年生存率明显降低，预后差。% BACKGROUND: With the deepening of tumor stem cel research, lung cancer stem cel s have become one of the research hotspots. OBJECTIVE: To evaluate the expression of tumor stem cel marker CD133 in lung cancer tissues, and to evaluate the correlation with the clinicopathologic characteristics of lung cancer. METHODS: Immunohistochemical staining was used to detect the positive expression rate of CD133 in lung cancer tissues with different types and differentiation degrees, as wel as to analyze the correlation between CD133 positive expression and the clinicopathologic characteristics, including the age, gender, size of the tumor, histological type, stage and grade, degree of differentiation, lymphatic metastasis and prognosis. RESULTS AND CONCLUSION: CD133 had higher positive expression rate in various types of lung cancer tissues, but the positive expression rate had correlation neither with the clinical characteristics of the patients including age and gender, nor with the histological type, stage and grade and the degree of differentiation. The positive expression rate was closely related with lymphatic metastasis and prognosis. The positive expression rate of CD133 was higher in the lung cancer tissues with lymphatic metastasis, and 5-year survival rate was significantly lower with poor prognosis.
展开▼
